Recent advances in AIDS-related cryptococcal meningitis treatment with an emphasis on resource limited settings

References

• Park BJ, Wannemuehler KA, Marston BJ, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23:525–530.
   PubMed Web of Science ®Google Scholar
• Durski KN, Kuntz KM, Yasukawa K, et al. Cost-effective diagnostic checklists for meningitis in resource-limited settings. J Acquir Immune Defic Syndr. 2013;63:e101–8.
   PubMed Web of Science ®Google Scholar
• Cogliati M. Global molecular epidemiology of Cryptococcus neoformans and Cryptococcus gattii: an atlas of the molecular types. Scientifica (Cairo). 2013;2013:675213.
   PubMedGoogle Scholar
• Chau TT, Mai NH, Phu NH, et al. A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in vietnam – high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease. BMC Infect Dis. 2010;10:199.
   PubMed Web of Science ®Google Scholar
• Park BJ, Shetty S, Ahlquist A, et al. Long-term follow-up and survival of antiretroviral-naive patients with cryptococcal meningitis in the pre-antiretroviral therapy era, Gauteng province, South Africa. Int J STD AIDS. 2011;22:199–203.
   PubMed Web of Science ®Google Scholar
• Lortholary O, Poizat G, Zeller V, et al. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS. 2006;20:2183–2191.
   PubMed Web of Science ®Google Scholar
• Jarvis JN, Boulle A, Loyse A, et al. High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. AIDS. 2009;23:1182–1183.
   PubMed Web of Science ®Google Scholar
• Carlson RD, Rolfes MA, Birkenkamp KE, et al. Predictors of neurocognitive outcomes on antiretroviral therapy after cryptococcal meningitis: a prospective cohort study. Metab Brain Dis. 2014;29:269–279.
   PubMed Web of Science ®Google Scholar
• Letang E, Muller MC, Ntamatungiro AJ, et al. Cryptococcal antigenemia in immunocompromised human immunodeficiency virus patients in rural Tanzania: a preventable cause of early mortality. Open Forum Infect Dis. 2015;2:ofv046.
   PubMed Web of Science ®Google Scholar
• Kaplan JE, Vallabhaneni S, Smith RM, et al. Cryptococcal antigen screening and early antifungal treatment to prevent cryptococcal meningitis: a review of the literature. J Acquir Immune Defic Syndr. 2015;68(Suppl 3):S331–9.
   Google Scholar
• Ssekitoleko R, Kamya MR, Reingold AL. Primary prophylaxis for cryptococcal meningitis and impact on mortality in HIV: a systematic review and meta-analysis. Future Virol. 2013;8:917–930.
   Web of Science ®Google Scholar
• Kapoor SW, Magambo KA, Kalluvya SE, et al. Six-month outcomes of HIV-infected patients given short-course fluconazole therapy for asymptomatic cryptococcal antigenemia. AIDS. 2015;29:2473–2478.
   PubMed Web of Science ®Google Scholar
• Mfinanga S, Chanda D, Kivuyo SL, et al. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. Lancet. 2015;385:2173–2182.
   PubMed Web of Science ®Google Scholar
• Boulware DR, Rolfes MA, Rajasingham R, et al. Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast. Emerg Infect Dis. 2014;20:45–53.
   PubMed Web of Science ®Google Scholar
• Kabanda T, Siedner MJ, Klausner JD, et al. Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid. Clin Infect Dis. 2014;58:113–116.
   PubMed Web of Science ®Google Scholar
• Vidal JE, Boulware DR. Lateral flow assay for cryptococcal antigen: an important advance to improve the continuum of HIV care and reduce cryptococcal meningitis-related mortality. Rev Inst Med Trop Sao Paulo. 2015;57(Suppl 19):38–45.
   PubMed Web of Science ®Google Scholar
• Wake RM, Glencross DK, Sriruttan C, et al. Cryptococcal antigen screening in HIV-infected adults: let’s get straight to the point. AIDS. 2016;30:339–342.
   PubMed Web of Science ®Google Scholar
• Rajasingham R, Meya DB, Boulware DR. Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr. 2012;59:e85–e91.
   PubMed Web of Science ®Google Scholar
• Jarvis JN, Govender N, Chiller T, et al. Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation. J Int Assoc Physicians AIDS Care (Chic). 2012;11:374–379.
   PubMedGoogle Scholar
• Southern African HIV Clinicians Society T. Guideline for the prevention, diagnosis and management of cryptococcal meningitis among HIV-infected persons: 2013 update. South Afr HIV. 2013;14:76.
   Web of Science ®Google Scholar
• Morawski BM, Boulware DR, Nalintya E, et al. Pre-ART cryptococcal antigen titer associated with preemptive fluconazole failure [abstract]. In: Conference on retroviruses and opportunistic infections (CROI). 2016 Feb 22–25; Boston (MA). IAS-USA/CROI Foundation. Abstract nr 159.
   Google Scholar
• Bicanic T, Muzoora C, Brouwer AE, et al. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis. 2009;49:702–709.
   PubMed Web of Science ®Google Scholar
• Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:291–322.
   PubMed Web of Science ®Google Scholar
• Hamill RJ, Sobel JD, El-Sadr W, et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis. 2010;51:225–232.
   PubMed Web of Science ®Google Scholar
• Day JN, Chau TT, Wolbers M, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013;368:1291–1302.
   PubMed Web of Science ®Google Scholar
• Merry M, Boulware DR. Cryptococcal meningitis treatment strategies affected by the explosive cost of flucytosine in the United States: a cost-effectiveness analysis. Clin Infect Dis. 2016;62:1564–1568.
   PubMed Web of Science ®Google Scholar
• Rajasingham R, Rolfes MA, Birkenkamp KE, et al. Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis. Plos Med. 2012;9:e1001316.
   PubMed Web of Science ®Google Scholar
• Grover N. Mylan to buy Swedish drugmaker meda in $7.2 billion deal. Thomson Reuters. 2016 [updated 2016 Nov 2; cited 2016 Jan 8]. Available from: http://www.reuters.com/article/us-meda-m-a-mylan-nl-idUSKCN0VJ2IK
   Google Scholar
• Adler-Moore JP, Gangneux JP, Pappas PG. Comparison between liposomal formulations of amphotericin B. Med Mycol. 2016;54:223–231.
   PubMed Web of Science ®Google Scholar
• Molefi M, Chofle AA, Molloy SF, et al. Ambition-cm: intermittent high dose ambisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial. Trials. 2015;16:276.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Chetchotisakd P, Larsen RA, et al. A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis. 2009;48:1775–1783.
   PubMed Web of Science ®Google Scholar
• Loyse A, Wilson D, Meintjes G, et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis. 2012;54:121–128.
   PubMed Web of Science ®Google Scholar
• Bahr NC, Rolfes MA, Musubire A, et al. Standardized electrolyte supplementation and fluid management improves survival during amphotericin therapy for cryptococcal meningitis in resource-limited settings. Open Forum Infect Dis. 2014;1:ofu070–ofu.
   PubMedGoogle Scholar
• Muzoora CK, Kabanda T, Ortu G, et al. Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis. J Infect. 2012;64:76–81.
   PubMed Web of Science ®Google Scholar
• Jackson AT, Nussbaum JC, Phulusa J, et al. A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis. AIDS. 2012;26:1363–1370.
   PubMed Web of Science ®Google Scholar
• Govender NP, Patel J, van Wyk M, et al. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002-2003 and 2007-2008. Antimicrob Agents Chemother. 2011;55:2606–2611.
   PubMed Web of Science ®Google Scholar
• Mdodo R, Moser SA, Jaoko W, et al. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates from AIDS patients in Kenya. Mycoses. 2011;54:e438–42.
   Web of Science ®Google Scholar
• Jarvis JN, Meintjes G, Rebe K, et al. Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS. 2012;26:1105–1113.
   PubMed Web of Science ®Google Scholar
• Jarvis JN, Meintjes G, Bicanic T, et al. Cerebrospinal fluid cytokine profiles predict risk of early mortality and immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis. Plos Pathog. 2015;11:e1004754.
   Google Scholar
• World Health Organization. Rapid advice: diagnosis, prevention and management of cryptococccal disease in HIV-infected adults, adolescents and children. 2011. [cited 2016 Nov 20]. Available from: http://www.who.int/hiv/pub/cryptococcal_disease2011/en/.
   Google Scholar
• Debruyne D. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin Pharmacokinet. 1997;33:52–77.
   PubMed Web of Science ®Google Scholar
• Rothe C, Sloan DJ, Goodson P, et al. A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, Malawi. PLoS One. 2013;8:e67311.
   PubMed Web of Science ®Google Scholar
• Longley N, Muzoora C, Taseera K, et al. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis. 2008;47:1556–1561.
   PubMed Web of Science ®Google Scholar
• Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis. 2007;45:76–80.
   PubMed Web of Science ®Google Scholar
• Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370:2487–2498.
   PubMed Web of Science ®Google Scholar
• Rhein J, Morawski BM, Hullsiek KH, et al. Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study. Lancet Infect Dis. 2016;16:809–818.
   PubMed Web of Science ®Google Scholar
• Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis. 2008;46:1694–1701.
   PubMed Web of Science ®Google Scholar
• Bozzette SA, Larsen RA, Chiu J, et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California collaborative treatment group. N Engl J Med. 1991;324:580–584.
   PubMed Web of Science ®Google Scholar
• Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med. 1992;326:83–89.
   PubMed Web of Science ®Google Scholar
• Saag MS, Cloud GA, Graybill JR, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases mycoses study group. Clin Infect Dis. 1999;28:291–296.
   PubMed Web of Science ®Google Scholar
• Sudan A, Livermore J, Howard SJ, et al. Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints. Antimicrob Agents Chemother. 2013;57:2793–2800.
   PubMed Web of Science ®Google Scholar
• Krysan DJ. Toward improved anti-cryptococcal drugs: novel molecules and repurposed drugs. Fungal Genet Biol. 2014;78:93–98.
   PubMed Web of Science ®Google Scholar
• Zhai B, Wu C, Wang L, et al. The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections. Antimicrob Agents Chemother. 2012;56:3758–3766.
   PubMed Web of Science ®Google Scholar
• Lewis RJ, Angier MK, Williamson KS, et al. Analysis of sertraline in postmortem fluids and tissues in 11 aviation accident victims. J Anal Toxicol. 2013;37:208–216.
   PubMed Web of Science ®Google Scholar
• Rolfes MA, Hullsiek KH, Rhein J, et al. The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis. Clin Infect Dis. 2014;59:1607–1614.
   PubMed Web of Science ®Google Scholar
• Butts A, Koselny K, Chabrier-Rosello Y, et al. Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo. MBio. 2014;5:e00765–13.
   PubMed Web of Science ®Google Scholar
• Colon JM, Miranda JD. Tamoxifen: an FDA approved drug with neuroprotective effects for spinal cord injury recovery. Neural Regen Res. 2016;11:1208–1211.
   PubMed Web of Science ®Google Scholar
• Rosen LB, Freeman AF, Yang LM, et al. Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis. J Immunol. 2013;190:3959–3966.
   PubMed Web of Science ®Google Scholar
• Chiller T, Farrokhshad K, Brummer E, et al. Effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on polymorphonuclear neutrophils, monocytes or monocyte-derived macrophages combined with voriconazole against Cryptococcus neoformansMed Mycol. 2002;40:21–26.
   PubMed Web of Science ®Google Scholar
• Lockhart SR, Fothergill AW, Iqbal N, et al. The investigational fungal cyp51 inhibitor VT-1129 demonstrates potent in vitro activity against Cryptococcus neoformans and Cryptococcus gattii. Antimicrob Agents Chemother. 2016;60:2528–2531.
   PubMed Web of Science ®Google Scholar
• Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs. 2013;73:919–934.
   PubMed Web of Science ®Google Scholar
• Indiamart. Flucytosine – ancotil 250mg/500mg capsule (exports only). Jolly Healthcare, Jaipur: Indiamart. [cited 2016 June 16]. Available from: http://www.indiamart.com/proddetail/flucytosine-ancotil-250mg-500mg-capsule-exports-only-8780636297.html
   Google Scholar
• Smith KD, Achan B, Hullsiek KH, et al. Increased antifungal drug resistance in clinical isolates of Cryptococcus neoformans in Uganda. Antimicrob Agents Chemother. 2015;59:7197–7204.
   PubMed Web of Science ®Google Scholar
• Bahr NC, Wallace J, Frosch AE, et al. Unmasking cryptococcal meningitis immune reconstitution inflammatory syndrome due to granulocyte colony-stimulating factor use in a patient with a poorly differentiated germ cell neoplasm. Case Rep Oncol. 2014;7:1–5.
   PubMedGoogle Scholar
• Beardsley J, Wolbers M, Kibengo FM, et al. Adjunctive dexamethasone in HIV-associated cryptococcal meningitis. N Engl J Med. 2016;374:542–554.
   PubMed Web of Science ®Google Scholar
• Newton PN, Thai Le H, Tip NQ, et al. A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis. 2002;35:769–772.
   PubMed Web of Science ®Google Scholar
• Loyse A, Wainwright H, Jarvis JN, et al. Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure. AIDS. 2010;24:405–410.
   PubMed Web of Science ®Google Scholar
• Robertson EJ, Najjuka G, Rolfes MA, et al. Cryptococcus neoformans ex vivo capsule size is associated with intracranial pressure and host immune response in HIV-associated cryptococcal meningitis. J Infect Dis. 2014;209:74–82.
   PubMed Web of Science ®Google Scholar
• Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin Infect Dis. 2000;30:47–54.
   PubMed Web of Science ®Google Scholar
• Bicanic T, Brouwer AE, Meintjes G, et al. Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS. 2009;23:701–706.
   PubMed Web of Science ®Google Scholar
• Meda J, Kalluvya S, Downs JA, et al. Cryptococcal meningitis management in Tanzania with strict schedule of serial lumber punctures using intravenous tubing sets: an operational research study. J Acquir Immune Defic Syndr. 2014;66:e31–6.
   Web of Science ®Google Scholar
• Nabeta HW, Bahr NC, Rhein J, et al. Accuracy of noninvasive intraocular pressure or optic nerve sheath diameter measurements for predicting elevated intracranial pressure in cryptococcal meningitis. Open Forum Infect Dis. 2014;1:ofu093.
   PubMedGoogle Scholar
• Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. Plos One. 2009;4:e5575.
   PubMed Web of Science ®Google Scholar
• Haddow LJ, Colebunders R, Meintjes G, et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis. 2010;10:791–802.
   PubMed Web of Science ®Google Scholar
• Longley N, Harrison TS, Jarvis JN. Cryptococcal immune reconstitution inflammatory syndrome. Curr Opin Infect Dis. 2013;26:26–34.
   PubMed Web of Science ®Google Scholar
• Katchanov J, Blechschmidt C, Nielsen K, et al. Cryptococcal meningoencephalitis relapse after an eight-year delay: an interplay of infection and immune reconstitution. Int J STD AIDS. 2015;26:912–914.
   PubMed Web of Science ®Google Scholar
• Chang CC, Dorasamy AA, Gosnell BI, et al. Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome. AIDS. 2013;27:2089–2099.
   PubMed Web of Science ®Google Scholar
• Boulware DR, Meya DB, Bergemann TL, et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. Plos Med. 2010;7:e1000384.
   PubMed Web of Science ®Google Scholar
• Makadzange AT, Ndhlovu CE, Takarinda K, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in Sub-Saharan Africa. Clin Infect Dis. 2010;50:1532–1538.
   PubMed Web of Science ®Google Scholar
• Bisson GP, Molefi M, Bellamy S, et al. Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis. Clin Infect Dis. 2013;56:1165–1173.
   PubMed Web of Science ®Google Scholar
• Boulware DR, Bonham SC, Meya DB, et al. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J Infect Dis. 2010;202:962–970.
   PubMed Web of Science ®Google Scholar
• Scriven JE, Lalloo DG, Meintjes G. Changing epidemiology of HIV-associated cryptococcosis in Sub-Saharan Africa. Lancet Infect Dis. 2016;16:891–892.
   PubMed Web of Science ®Google Scholar
• Jarvis JN, Meintjes G, Harrison TS. Outcomes of cryptococcal meningitis in antiretroviral naive and experienced patients in South Africa. J Infect. 2010;60:496–498.
   PubMed Web of Science ®Google Scholar
• Musubire AK, Boulware DR, Meya DB, et al. Diagnosis and management of cryptococcal relapse. J AIDS Clin Res. 2013;Suppl 3:S3- 003.
   PubMedGoogle Scholar
• Jarvis JN, Meintjes G, Williams Z, et al. Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: the role of inadequate secondary prophylaxis. S Afr Med J. 2010;100:378–382.
   PubMed Web of Science ®Google Scholar
• Gamaletsou MN, Sipsas NV, Kontoyiannis DP, et al. Successful salvage therapy of refractory HIV-related cryptococcal meningitis with the combination of liposomal amphotericin B, voriconazole, and recombinant interferon-gamma. Diagn Microbiol Infect Dis. 2012;74:409–411.
   PubMed Web of Science ®Google Scholar
• Brunel AS, Reynes J, Tuaillon E, et al. Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS. AIDS. 2012;26:2110–2112.
   PubMed Web of Science ®Google Scholar
• Sitapati AM, Kao CL, Cachay ER, et al. Treatment of HIV-related inflammatory cerebral cryptococcoma with adalimumab. Clin Infect Dis. 2010;50:e7–10.
   Google Scholar